Research Article

Network Pharmacology, Molecular Docking, and Experimental Validation to Unveil the Molecular Targets and Mechanisms of Compound Fuling Granule to Treat Ovarian Cancer

Zhaoyi Li, Qingling Liu, Ying Zhu, Lichao Wu, Wenhong Liu, Junfeng Li, Zhiqian Zhang, and Fangfang Tao

1Department of Dermatology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, China
2Department of Immunology and Microbiology, School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
3Department of Medical Oncology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310053, China
4State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300071, China

Correspondence should be addressed to Zhiqian Zhang; zhangzq@sustech.edu.cn and Fangfang Tao; taoff@zcmu.edu.cn

Received 13 July 2022; Revised 6 August 2022; Accepted 8 August 2022; Published 23 August 2022

Academic Editor: Md Sayed Ali Sheikh

Copyright © 2022 Zhaoyi Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Compound fuling granule (CFG) is a traditional Chinese medicine formula that is used for more than twenty years to treat ovarian cancer (OC) in China. However, the underlying processes have yet to be completely understood. This research is aimed at uncovering its molecular mechanism and identifying possible therapeutic targets. Methods. Significant genes were collected from Therapeutic Target Database and Database of Gene-Disease Associations. The components of CFG were analyzed by LC-MS/MS, and the active components of CFG were screened according to their oral bioavailability and drug-likeness index. The validated targets were extracted from PharmMapper and PubChem databases. Venn diagram and STRING website diagrams were used to identify intersection targets, and a protein–protein interaction network was prepared using STRING. The ingredient-target network was established using Cytoscape. Molecular docking was performed to visualize the molecule–protein interactions using PyMOL 2.3. Enrichment and pathway analyses were performed using FunRich software and Reactome pathway, respectively. Experimental validations, including CCK-8 assay, wound-scratch assay, flow cytometry, western blot assay, histopathological examination, and immunohistochemistry, were conducted to verify the effects of CFG on OC cells. Results. A total of 56 bioactive ingredients of CFG and 185 CFG-OC-related targets were screened by network pharmacology analysis. The potential therapeutic targets included moesin, glutathione S-transferase kappa 1, ribonuclease III (DICER1), mucin1 (MUC1), cyclin-dependent kinase 2 (CDK2), E1A binding protein p300, and transcription activator BRG1. Reactome analysis showed 51 signaling pathways (P < 0.05), and FunRich revealed 44 signaling pathways that might play an important role in CFG against OC. Molecular docking of CDK2 and five active compounds (baicalin, ignavine, lactiflavin, neokadsuranic acid B, and deoxyaconitine) showed that baicalin had the highest affinity to CDK2. Experimental approaches confirmed that CFG could apparently inhibit OC cell proliferation and migration in vitro; increase apoptosis; decrease the protein expression of MUC1, DICER1, and CDK2; and suppress the progression and distant metastasis of OC in vivo. DICER1, a tumor suppressor, is essential for microRNA synthesis. Our findings suggest that CFG may impair the production of miRNAs in OC cells. Conclusion. Based on network pharmacology, molecular docking, and experimental validation, the potential mechanism underlying the function of CFG in OC was explored, which supplies the theoretical groundwork for additional pharmacological investigation.
1. Introduction

According to worldwide statistics, in 2018, approximately 295,414 cases of newly diagnosed ovarian cancer (OC) were reported, and the number of OC-induced fatalities had increased to 184,799 [1]. Epithelial ovarian cancer, the most common histological type among women of all racial or ethnic groups, accounts for 90% of all cases of OC [2]. Constituting 3.4% of primarily diagnosed female cancer in women and 4.4% of the death toll with five-year survival rate of 48% [3, 4], OC is the most lethal gynecological malignancy [1]. Only 15% of identifiable OCs can be diagnosed at an early stage [5]. Unfortunately, the majority of patients are presented with advanced stage at the time of diagnosis, resulting in a dismal prognosis [6]. Despite initial susceptibility to paclitaxel and carboplatin combinational chemotherapy in nearly 80% of patients, around half of them eventually develop acquired drug resistance within 5 years and disease relapse [7]. Therefore, identification of novel biomarkers and possible targets is imperative to improve the efficacy of clinical diagnosis and treatment.

Compound fuling granule (CFG), has been utilized as a traditional Chinese formula to treat OC in China for two decades. CFG consists of four herbs, Aconitum napellus (monkshood) (FZ), Wolfiporia extensa (Peck) Ginnis (FL) (formerly known as Poria cocos F.A. Wolf), Patrinia heterophylla DC (Diversilobous patrirnia) root (MTH), and Radix paeoniae Rubra (CS) (red peony root). CFG inhibited OC development and progression through interfering with mitochondrial activity and galactose and fatty acid metabolism [8]. However, the underlying mechanisms have yet to be completely understood.

The network pharmacology approach, first proposed by Hopkins [9], has greatly promoted theoretical studies on effective ingredients and targets in traditional Chinese formula [10]. The approach was used in a multilayered network to discover interactions between bioactive ingredients and targets to identify and confirm critical nodes via network analysis and verification [11]. With the wide use of this approach and enrichment of the clinical experience of traditional Chinese medicine (TCM) treatment over thousands of years, transformation from the one drug, one model to the “network targets, multicomponent” model would hopefully be realized in the near future [12]. Molecular docking is a process of spatially docking a small molecule onto a macromolecule and quantifying the complementary value at the binding site, which is quantitatively scored, facilitating structure-based medication design [13].

The entire research flowchart of the present study is presented in Figure 1: (1) significant gene targets of OC were screened out, (2) ingredients of the four herbs in CFG and the corresponding gene targets were selected, (3) gene targets of OC and the herbs were selected for network pharmacology analysis and forecast possible predicting the potential targets and pathways of CFG against OC, and (4) the underlying mechanism of CFG in OC was validated by performing various experiments.

2. Materials and Methods

2.1. Collection of Significant Genes in OC. The Therapeutic Target Database (TTD) (https://db.idrblab.org/ttd/) and Gene-disease Associations Database (DisGeNET) (http://www.disgenet.org/web/DisGeNET/menu/home) were used for collecting significant genes in OC. The following criteria were used for the collection: (1) the indication should include “ovarian cancer” in the TTD; (2) the gda score of the genes collected from the DisGeNET should be ≥0.02. The two databases’ overlapping genes were eliminated. Various gene IDs were converted into UniProt numbers using UniProtKB (http://www.uniprot.org/) to normalize the obtained gene information.

2.2. Herb Formulation Compound Collection and Target Fishing. Herb formulation compounds were retrieved from TCM databases such as TCM Systems Pharmacology (TCMSP) Database (http://lsp.nwsuaf.edu.cn/tcmsp.php) and TCM Integrated Database (TCMD, http://www.megabionet.org/tcmid/). The compounds were filtered according to the criterion with absorption, distribution, metabolism, and elimination (ADME) parameters in the TCMSP database. Drug-likeness (DL) index ≥0.18 and the oral bioavailability (OB) value ≥30% were considered for the screening.

To obtain the probable targets of the plant compounds, we performed target fishing. The validated targets were extracted from PubChem (https://pubchem.ncbi.nlm.nih.gov/). We collected these predicted targets of CFG using PharmMapper based on active small molecules in SDF format (http://filab.ecust.cn/pharmmapper/).

2.3. Network Construction and Analysis. First, we used an online Venn diagram website (http://www.bioinformatics.com.cn/static/others/venn/example.html) to identify the intersection of the OC and CFG targets, obtain common targets of drugs and diseases, and draw Venn diagrams. For the intersection targets, the STRING11.0 database (https://cn.string-db.org/) was used to construct a protein–protein interaction (PPI) network of common targets. The tsv files were downloaded and imported into the Cytoscape software for visualization. Common gene targets of the OC and CFG molecules were retained and matched with the corresponding code names of the ingredients in Excel 2017 to build an ingredient-target database. The Cytoscape software (version 3.2.1) was operated to establish ingredient–target networks and generate network pharmacology images. Then, the Cytoscape plugin, cytoHubba (http://apps.cytoscape.org/media/cytohubba/releases/0.1/cytoHubba-impl-0.1.jar), was used to determine topological characteristics such as degree, betweenness, proximity, and eccentricity. The top 10 nodes for each parameter were chosen in order to investigate the crucial nodes that correspond to potential major ingredients and major targets for herbs.

2.4. Enrichment Analysis and Pathway Analysis. To further understand the role of the targets of OC, we identified pivotal pathways by the enrichment analysis of the gene targets using the Reactome pathway database (https://reactome.org/
Network pharmacology

Gene database ↔ OC gene database

304 significant gene targets

Gene targets corresponding with ingredients

Representative gene targets

Ingredients

(Herbs database)

Precision treatment of TCM

Herb ingredients

Gene targets

Clear biological effects

Precision treatment of TCM

Figure 1: Process overview. (1) Significant gene targets of OC were screened out, (2) ingredients of the four herbs in CFG and the corresponding gene targets were selected, (3) gene targets of OC and the herbs were selected for network pharmacology analysis and forecast possible predicting the potential targets and pathways of CFG against OC, and (4) the underlying mechanism of CFG in OC was validated by performing various experiments.

PathwayBrowser/) and the FunRich software. Therefore, the biomarkers and potential targets via which CFG affected OC could be mapped on the target–pathway networks, and the mechanisms of CFG underlying OC could be visually understood.

2.5. Molecular Docking. The three-dimensional structures of the proteins were downloaded from the RCSB PDB database (https://www.rcsb.org/), and those of the molecule ligands were retrieved from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). The proteins and ligands were uploaded into the DockThor tool (https://docthor.lncc.br/v2/) to take away water molecules, perform hydrogenation, and calculate charges on the proteins. The final docking conformation was selected based on its strong affinity and was shown in PyMOL 2.3.

2.6. CFG Preparations. The herbs were supplied by Zhejiang Provincial Hospital of TCM, Zhejiang, China, which were identified by associate professor Bo Yang at the College of Pharmaceutical Sciences, Zhejiang Chinese Medical University. Their Chinese, English, and Latin names; family; portion utilized; location; their families; parts used; places of origin; voucher numbers; daily adult dosages (g); and ratio all included ratios were reported in the previous publication [8]. The Plant List (http://www.theplantlist.org) provided validated information of the herb names with taxonomic validity. A previously published CFG preparation method was followed [8]. In brief, the four constituent herbs were mixed in a 1:1:1:1 ratio and extracted twice for 1 hour each time using 75% ethanol (1:10, w/w). CFG was dissolved in a cell culture medium containing 2% fetal calf serum to obtain the drug stock solution (6 mg/mL). After filtration and sterilization using a 0.2 μm bacterial percolator to eliminate the effect of serum and other substances in the culture medium, the solution was diluted to 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL, and 2 mg/mL.

2.7. Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) Analysis. Data were collected using an ultra-high-performance liquid phase (Waters Acquity UPLC™ I-class system, Waters Corp, Milford, MA, USA) coupled with a high-resolution time-of-flight mass spectrometer (Waters Xevo G2 QTof, Waters Corp., Milford, MA, USA). Chromatography was performed using Waters UPLC HSS T3 at 40°C. The data were processed using Waters MassLynx 4.1. The mobile phase was water (A) and acetonitrile (B) containing 0.1% formic acid, the flow rate was 0.3 mL/min, and the elution conditions were as follows: 0–2 min, 0–5% B; 2–10 min, 5%–15% B; 10–15 min, 15%–25% B; 15–18 min, 25%–50% B; 18–23 min, 50%–100% B; 23–25 min, 100%–2% B; and 25–30 min, 2% B. The injection volume was 2 μL. The mass spectra were obtained in Fast DDA and positive ion mode, with an ESI ion source, and the following settings were used: electrospray ionization ion scan range: 50–2000 m/z; capillary voltage: 3.0 kV; ion source temperature: 100°C; desolvation gas (N_2) temperature: 350°C; desolvation gas flow rate: 1000 L/h; cone gas flow rate (N_2): 100 L/h; and collision gas: argon.
2.8. Molecular Networking. The raw data of CFG acquired from LC-ESI-Q-TOF/MS were converted into mzXML files using the msConvert software. Then, the mzXML file data were uploaded onto Global Natural Products Social Molecular Networking (GNPS, http://gnps.ucsd.edu) for molecular networking using an online workflow. To generate consensus spectra, data were then clustered with a parent mass tolerance of 0.05 Da and an MS/MS fragment ion tolerance of 0.5 Da. Furthermore, consensus spectra less than two spectra were discarded. Edges with cosine scores greater than 0.6 were filtered out. Cytoscape 3.9.0 was used to visualize the results. The output from the molecular networking was visualized using Cytoscape 3.9.0. After incorporating the in silico structural annotation information from Network Annotation Propagation (NAP) [14], DEREPPLICATOR [15], and MS2LDA [16], a comprehensive chemical overview of the metabolomics information in the molecular networking was achieved using a GNPS MolNetEnhancer workflow [17]. The chemical classification was performed using ClassyFire [18].

2.9. Cell Culture. SKOV3 and HEY cells were obtained from National Collection of Authenticated Cell Cultures (Beijing, China). The cells were cultured with RPMI 1640 and McCoy’s 5A media, respectively, supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin, and the cell culture was maintained at 37°C in a humidified chamber with 5% CO₂. After reaching 80% confluence, the cells were continuously exposed to different concentrations of CFG for 24 h.

2.10. Cell Counting Kit-8 (CCK-8) Assay. The cell viabilities of CFG in SKOV3 and HEY cells were determined using the CCK-8 assay. In 96-well plates, cells were sown at a density of 5 × 10³ cells per well. The next day, cells were treated with CFG at different concentrations of CFG (0, 0.25, 0.5, 1, and 2 mg/mL) for 24 hours. After adding CCK8 reagent to each well for 30 minutes, the absorbance at 450 nm was measured.

2.11. Wound-Scratch Assay. A wound-scratch assay was performed as described previously [19]. After creating the wound area, the cells were exposed to CFG for 12 h and 24 h, and the images of the wound area were obtained and analyzed using the ImageJ software.

2.12. Apoptosis and Cell Cycle Detection by Flow Cytometry. Apoptotic SKOV3 and HEY cells were quantified using the Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (Beyotime, Shanghai, China). The cells were resuspended in the Annexin-V Binding Buffer with 10 μL of FITC and 5 μL of PI. The cells were incubated at room temperature for 30 minutes in the dark, and the samples were collected and detected using a CytoFLEX flow cytometer (Beckman Coulter, Miami, FL, USA).

For cell cycle analysis, the cells were treated with 70% cold ethanol for 24 h and stained with PI (RNase A-free) for 30 minutes at room temperature after fixation in 70% ice-cold ethanol overnight at 4°C. Each sample was detected using the CytoFLEX S flow cytometer (Beckman Coulter), and data were analyzed using the ModFit 3.1 software (BD Biosciences, San Jose, CA, USA).

2.13. Western Blot Assay. Cell proteins were collected using a radioimmunoprecipitation assay lysis buffer (Yuanye Bio, Shanghai, China) containing 1 mM phenylmethylsulfonyl fluoride (Yuanye Bio, Shanghai, China). A total of 20 μg protein per well was electrophoresed in 8% sodium dodecyl sulfate–polyacrylamide gel before being transferred to polyvinylidene difluoride membranes. The membranes were incubated with various primary antibodies, including cyclin-dependent kinase 2 (CDK2) (Abcam ab32147, Shanghai, China), mucin 1 (MUC1) (1 : 1000 Cell Signaling Technology 4538S, Danvers, MA, USA), ribonuclease III (DICER1) (1 : 1000 Abcam ab14601), and β-actin (ImmunoWay Biotechnology Company YM3028, Plano, TX, USA) at 4°C overnight. The membranes were then treated with antirabbit immunoglobulin G (IgG) (ImmunoWay Biotechnology Company R50002) or anti-mouse IgG (ImmunoWay Biotechnology Company R50001) at room temperature for 2 h. All bands were detected using an ECL western blot kit (Biosharp, Hefei, China). β-Actin was used as an internal control. The experiments were performed in triplicate.

2.14. Animals and Treatment. The Institutional Animal Care and Use Committee of Zhejiang Chinese Medical University approved all animal procedures prior to the initiation of this study (Approval No. 2022-KL-099-01). Female BALB/c (nu/nu) mice (20 ± 1 g, 4-6-week-old) (Beijing Vital River Laboratories, Beijing, China) with SKOV3 cells were used for verifying the effects of the ethanol extract of CFG on OC. Previous experiments confirmed that 30 mg/kg was the optimal therapeutic CFG dose in an OC mouse model [8]. For the control group (6 mice), 100 μL PBS was administered by intragastric gavage daily for 44 days. 5 × 10⁶ SKOV3 cells were tail intravenous injected in the 15th day; for the CFG group (6 mice), 30 mg/kg CFG group with subcutaneous injection, 30 mg/kg CFG was administered by intragastric gavage daily for 44 days. 5 × 10⁶ SKOV3 cells were inguinal subcutaneous injected once in the 15th day. Every 7 days, the weight of mice was monitored. At the 44th day, the mice were sacrificed, and lung tissues were collected for further analysis.

2.15. Hematoxylin and Eosin (H&E) Staining and Immunohistochemistry (IHC). H&E staining: the lung tissues were paraffin-embedded and cut into 45 μm thick sections. The slices were dewaxed with xylene, dehydrated with gradient alcohol, and stained with after embedding and paraffin sectioning. The slices were photographed under a light microscope (100x).

IHC: the sections were deparaffinized, rehydrated, and then subjected to antigen retrieval for 10 minutes in an antigen retrieval buffer. Next, the sections were then treated with 3% H₂O₂ for 15 minutes at room temperature to block the activity of endogenous peroxidases. After that, the sections were incubated with goat serum to prevent nonspecific binding for 15 minutes. Afterward, these sections were incubated overnight at 4°C with the MUC1 antibody (dilution: 1 : 200,
Cell Signaling Technology 4538S) or the CDK2 antibody (dilution: 1:200, Abcam ab32147). The next day, the sections were incubated with the corresponding secondary antibodies (dilution: 1:500; Thermo Fisher Scientific, USA) for 1 hour at 37°C. The sections were then stained with DAB (3, 3′-diaminobenzidine) Kit (Bioyoite) for 5 min and examined using a light microscope at 100x magnification.

2.16. Statistical Analysis. Data analysis was performed using SPSS 20.0 (SPSS for Windows, Chicago, SPSS Inc.). The experiment was done three times, and the data are expressed as the mean ± standard deviation (x ± s). Means among multiple groups were compared by one-way analysis of variance, and t-test was performed for pair comparison between the groups. P < 0.05 was considered statistically significant.

3. Results

3.1. Active Compounds and Metabolite Diversity Analysis of CFG. CFG alcohol extract samples were analyzed by LC-MS/MS (Figure 2(a)). A total of 36 known CFG compounds were found (Table 1), and six met the criteria of OB ≥ 30% and DL index ≥ 0.18. These six compounds were as follows: kumatakenin, karakoline, (epi)catechin, tetrahydrocolumbamine, acacetin-7-O-neohesperidoside, and hypaconitine. In the present study, GNPS was first used to probe the chemical compounds in CFG (https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=3fa7c6d72751497baee7914a7db0d6cc). A total of 3917 precursor ions were visualized as nodes in the status.jsp?task=3fa7c6d72751497baee7914a7db0d6cc nodes (15%), such as organooxygen compounds, carboxylic acids and derivatives, and benzene and substituted derivatives, shown in different colors (Figure 2(b)). The result indicated the chemical diversity of metabolites in CFG.

3.2. Compound and Disease Target Prediction. To enrich the types of TCM compounds, we identified more compound types of CFG using the TCMSP and TCMD database. After removing duplicates and performing ADME screening, a total of 56 compounds were obtained after eliminating duplicates and completing ADME screening. As for the compounds of the four herbs in CFG, 23, 18, 14, and 1 compounds were of CS, FZ, FL, and MTH, respectively, based on the criteria of DL ≥ 0.18 and OB ≥ 30%. For all 16486 targets, 5382 targets of FZ, 4186 of FL, 299 of MTH, and 6619 of CS were collected.

A total of 304 OC-related targets were screened out from TTD (n = 33) and DisGeNET (n = 271) after isolating the duplicated genes (Supplemental table 1). The online Venn diagram website was used to obtain the common targets of drugs and diseases and draw Venn diagrams (Figure 3(a)). A total of 185 common gene targets were selected for OC- and CFG-related molecules to build an ingredient-target database (Supplemental table 2). Their distribution was as follows: 65 targets were of OC and FZ, 45 were of OC and FL, 72 were of OC and CS, and 3 were of OC and MTH. To build a PPI network, the 185 common targets were uploaded into the STRING website. There were 43 nodes with 112 edges after free targets were removed (Figure 3(b)).

3.3. Potential Major Ingredients and Key Targets of the Four Herbs. The major components and objectives of each plant are given in Table 2, and the images of network pharmacology results are presented in Figures 3(c)–3(f). The diamond-shaped nodes indicate the ingredients, and the circular nodes symbolize the targets. Based on the declining sequence of degree values, the colors were converted from red to yellow based on the descending order of degree values.

As depicted in Figure 3(c), the FZ network comprised 58 nodes with nine major ingredients, namely, hypaconitine, 11,14-eicosadienoic acid, demethylelvanalve A, demethylelavaine B, neokadsuranic acid B, 6-demethylesdoline, deoxyaconitine, ignavine, and isotalatizidine. The major targets of FZ for OC treatment were ABO, SOD2, IL6ST, DICER1, CDK2, CCND1, AKR1C1, ABL1, and ADAM17. Figure 3(d) shows that the FL network consisted of 27 nodes. A total of 10 compounds, including trametenolic acid, 7,9(11)-dehydropropachymic acid, cereviseterol, and pachymic acid, were the major ingredients, and the major targets were GSTK1, NCOA3, MSN, SOD2, SMARCA4, and MUC1. A total of 45 nodes shown in Figure 3(e) constituted the CS network. The compounds including stigmasterol, lactiflorin, paeninflorin, paeninflorin_qt, benzoyl paeninflorin, albi-florin, paoniflorigenone, and evofovin B were the major ingredients. CDK2, GSTK1, MSN, NCOA3, NDC80, and SMARCA4 were the major targets. Figure 3(f) shows four nodes that formed the MTH network. Quercetin represented the major ingredient, and the major targets were GJA1, NFATC1, and GSTK1.

3.4. Major Common Targets and Underlying Pharmacological Mechanisms of CFG for OC Treatment. The key shared targets for the four herbs are depicted in Figure 3(g), among which seven were common targets of three herbs, and nine were common between two herbs. The representative common genes included MSN, GSTK1, DICER1, MUC1, CDK2, EP300, and SMARCA4. These were possible key CFG targets against OC treatment.

Gene enrichment analysis showed a total of 51 signaling pathways in the Reactome analysis (P < 0.05) (Supplemental table 3) and 44 (P < 0.05) in the FunRich analysis.
Figure 2: LC-MS/MS analysis of CFG. (a) Peak chromatograms of the alcohol extract of CFG by LC-MS/MS. (b) Clusters corresponding to CFG extracts with GNPS.
Table 1: Tentative identification of chemical compounds in CFG by LC-MS/MS, 36 is known.

| Compound | Retention time (min) | MS1       | MS2       | Tentative compounds | Source               |
|----------|----------------------|-----------|-----------|----------------------|----------------------|
| 1        | 2.43                 | 268.1053  | 136.06    | Adenosine            | Mutouhui, Fuzi, Fuling, Max |
| 2        | 136.0628             | 119.04    |           | Adenine              | Fuzi, Fuling, Max     |
| 3        | 152.0626             |           |           |                      |                      |
| 4        | 3.04                 | 166.0872  | 120.08, 103.05 | Phenylalanine       | Mutouhui, Fuzi, Fuling, Max |
| 5        | 3.10                 | 315.0719  | 153.02    | Kumatakenin          | Chishao, Max          |
| 6        | 5.39                 | 486.2712  | 422.21, 404.22 |                      |                      |
| 7        | 5.58                 | 171.1020  | 153.09, 125.09, 107.09 | Gallic acid        | Mutouhui, Max         |
| 8        | 5.74                 | 424.2701  |           |                      |                      |
| 9        | 5.93                 | 378.2650  | 360.25    | Karakoline           | Fuzi, Max             |
| 10       | 6.29                 | 579.1492  | 427.11, 409.08, 287.06, 127.04 | Procyanidin B2    | Fuziline              |
| 11       | 6.49                 | 358.2394  | 340.23    | Bullatine G         | Max                   |
| 12       | 7.19                 | 291.0873  | 139.04, 123.04 | (Epi)catechin    | Chishao               |
| 13       | 163.0402             |           | 145.03, 135.05, 117.04, 89.04 | Caffeic acid      | Fuzi, Mutouhui, Max   |
| 14       | 7.77                 | 454.2824  | 436.27, 404.23 |                      | Fuzilin               |
| 15       | 867.2244             | 545.12, 409.08, 287.05, 275.05 |                      | Procyanidin trimer | Mutouhui, Max         |
| 16       | 1155.26              | 867.21, 577.28, 287.05, 275.05 |                      | Procyanidin tetramer | Mutouhui, Max         |
| 17       | 8.41                 | 438.2876  | 420.28, 388.24 |                      | Bullatine B         | Fuzi, Max             |
| 18       | 8.80                 | 342.1708  | 297.11, 265.09 |                      | Tetrahydrocolumbamine | Fuzi, Mutouhui, Max   |
| 19       | 9.07                 | 454.2805  | 422.25, 404.26, 372.23 |                      | Isomer of fuziline | Fuzi, Max             |
| 20       | 9.33                 | 359.1352  | 197.08, 127.04 |                      | Sweroside            | Mutouhui, Max         |
| 21       | 9.56                 | 177.0560  | 131.05    |                      | Ferulic acid         | Fuzi, Mutouhui, Max   |
| 22       | 9.81                 | 481.1724  | 319.11, 301.10, 249.08, 197.08 | Terpene glycosides | Chishao, Max         |
| 23       | 11.00                | 463.2169  | 245.10, 201.11, 183.10, 165.09, 137.09 | Unknown           | Mutouhui, Max         |
| 24       | 11.31                | 452.3015  | 420.28, 388.25 |                      | Chasmanine          | Fuzi, Max             |
| 25       | 11.60                | 469.1707  | 307.12, 289.11 |                      | Cimifugin 4'-O-beta-D-glucopyranoside | Mutouhui, Chishao, Max |
| 26       | 661.1785             | 449.12, 319.08, 163.04 |                      | Cinnamic acids and derivatives | Mutouhui, Max         |
| 27       | 11.82                | 459.28    | 133.09, 89.06 |                      | Decaethylene glycol | All                   |
| 28       | 12.95                | 625.1793  | 463.12, 317.07 |                      | Isorhamnetin-3-O-rutinoside | Chishao             |
| 29       | 13.48                | 307.1152  | 289.11, 259.06, 235.06 |                      | Cimifugin            | Chishao, Mutouhui, Max |
| 30       | 13.64                | 463.3073  | 301.18    |                      | Peonidin-3-glucoside | Mutouhui, Max         |
| 31       | 427.2889             | 409.27, 373.27, 353.20, 331.22, 301.17, 255.17, 191.12, 173.09 |                      | Ecdysteroids         | Mutouhui, Max         |
| 32       | 14.18                | 481.1720  | 197.08, 179.07, 161.06, 151.07, 133.06, 105.03 | Terpene glycosides | Chishao, Max         |
| 33       | 499.1257             | 319.08, 163.04 |                      | Cinnamic acids and derivatives | Mutouhui, Max         |
| 34       | 585.2186             | 453.17, 291.12, 273.11 |                      |                      | Fuling, Max           |
| 35       | 14.89                | 609.1763  | 463.13, 301.07 |                      | Diosmetin-7-O-rutinoside | Mutouhui             |
| Compound | Retention time (min) | MS1     | MS2               | Tentative compounds          | Source            |
|----------|----------------------|---------|-------------------|------------------------------|------------------|
| 36       | 15.71                | 604.3149| 586.31, 572.28, 554.27, 540.25 | 14-Benzoylaconine           | Fuzi, Max        |
| 37       | 16.34                | 574.3016| 542.28, 105.03    | Benzoylhypaconine            | Fuzi, Max        |
| 38       | 17.00                | 593.19  | 447.14, 285.07    | Acacetin-7-O-neohesperidoside | Mutouhui, Max    |
| 39       | 17.10                | 433.1095| 287.05            | Kaempferol-3-O-rhamnoside    | Mutouhui, Chishao, Max |
| 40       | 17.26                | 632.3061| 572.29, 540.27, 354.17 | Mesaconitine                | Fuzi, Max        |
| 41       | 17.59                | 616.3127| 556.29, 524.27, 496.26, 338.18 | Hypeaconitine               | Fuzi, Max        |
Figure 3: Continued.
Figure 3: Continued.
Figure 3: Continued.
Cytokine signaling in the immune system, signaling by interleukins, mitotic G1-G1/S phase signaling, and innate immune system-related pathways were discovered in the Reactome pathway analysis. FunRich analysis showed that antiapoptosis, cell proliferation, chromosome segregation, and gene silencing were closely associated with several biological pathways, mainly including the epidermal growth factor receptor (ErbB) signaling pathway, phosphoinositol 3 kinase- (PI3K-) protein kinase B (Akt) signaling pathway, mammalian target of rapamycin (mTOR) signaling pathway, and cell division control protein 42 (CDC42) signaling pathway (Figure 4(a)).

The pathway map showed that TCM played an anti-OC role by exhibiting cyto-biological effects such as cytotoxicity, mutagenicity, DNA repair, therapy resistance, apoptosis, proliferation, migration, and translocation (Figure 4(b)).

3.5. Results of the Molecular Docking of Active Ingredients and CDK2. Molecular docking was performed to determine if the main constituent has an important role in CDK2 regulation. The docking results showed that five compounds, namely, baicalin, ignavine, lactiflorin, neokadsuronic acid B, and deoxyaconitine, in the network showed strong affinity toward CDK2 (Figures 5(a)–5(e)). Baicalin formed six hydrogen bonds with the amino acid residues (Supplemental table 4).
LYS-66, LYS-22, VAL-127, LEU128, ARG67, and SER71 which formed the most stable complex with CDK2. Moreover, ignavine formed five hydrogen bonds with amino acid residues LYS57, ASR69, VAL70, LEU68, and LEU67; lactiflorin formed four hydrogen bonds with LYS22, ASP131, LEU128, and ARG67; neokadsuranic acid B formed three hydrogen bonds with LYS22, LYS66, and ARG67; and deoxyaconitine formed one hydrogen bond with LYS57.

3.6. Experimental Validation. Three putative major targets, namely, MUC1, DICER1, and CDK2, were chosen for experimental validation to further validate the predicted results of network pharmacology. OC cell lines SKOV3 and HEY and in vivo mouse model were used to investigate and validate the effects of the ethanol extract of CFG.

The results clarified that CFG inhibited cell proliferation at a dose of 0.5, 1, and 2 mg/mL in vitro \((P < 0.05)\) in a dose-dependent manner (Figure 6(a)). As 2 mg/mL CFG overy

| Chinese name | Latin name | Number of ingredients | Major ingredients | Major targets |
|--------------|------------|-----------------------|-------------------|--------------|
| Fuzi (FZ)    | Aconitum napellus | 18                  | (FZ02) hypaconitine (FZ03) 11,14-eicosadienoic acid (FZ05) demethylavaine A (FZ06) demethylavaine B (FZ09) neokadsuranic acid B (FZ12) 6-demethyldesoline (FZ13) deoxyaconitine (FZ14) ignavine (FZ15) isotalatizidine | ABO SOD2 IL6ST DICER1 CDK2 CCND1 AKR1C1 ABL1 ADAM17 |
| Fuling (FL)  | Wolfiporia extensa (Peck) Ginns | 14                  | (FL-01) (2R)-2-[(3S,5S,10S,13R,14R,16R,17R)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-enoic acid (FL-02) trametenolic acid (FL-03) 7,9(11)-dehydropachymic acid (FL-04) cerevisterol (FL-05) (2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-5-isopropyl-hex-5-enoic acid (FL-08) 3beta-hydroxy-24-methylene-8-lanostane-21-oic acid (FL-09) pachymic acid (FL-10) poricoic acid A (FL-11) poricoic acid B (FL-14) dehydroeburicoic acid | GSTK1 NCOA3 MSN SOD2 SMARCA4 MUC1 |
| Chishao (CS) | Radix paeoniae Rubra | 23                  | (CS-03) stigmasterol (CS-05) lactiflorin (CS-06) paeoniflorin (CS-07) paeoniflorin_qt (CS-12) 1-o-beta-d-glucopyranosyl-8-o-benzoylpaeonisuffrone_qt (CS-15) benzyol paeoniflorin (CS-16) albilflower (CS-18) 4-ethyl-paeoniflorin_qt (CS-19) 4-o-methyl-paeoniflorin_qt (CS-21) paeoniflorigenone (CS-22) evofolin B (CS-23) isobenzoylpaeoniflorin | CDK2 GSTK1 MSN NCOA3 NDC80 SMARCA4 |
| Mutouhui (MTH) | Patrinia heterophylla DC root | 1                   | (MTH) quercetin | GJA1 NFATC1 GSTK1 |
Figure 4: The biological pathway for CFG on ovarian cancer analyzed by FunRich software. (a) Simplified pathways in OC. (b) All targets are shown in terms of gene names.
Figure 5: Continued.
weakened cell viability, doses of 0.25 mg/mL, 0.5 mg/mL, and 1 mg/mL were marked as low, medium, and high and selected for further experiments. The effects of CFG on cell migration are shown in Figures 6(b)–6(e), in which CFG was verified to inhibit cell migration (P < 0.01).

As presented in Figures 6(f) and 6(g), an increased apoptosis rate was detected by flow cytometry, when the cells were treated with increased concentrations of CFG. The difference was statistically significant at a dose of 0.5 mg/mL in SKOV3 cells (P < 0.01) and 1 mg/mL in HEY cells (P < 0.01), compared with parental cells, suggesting that CFG accelerated OC cell apoptosis. Simultaneously, the percentage of the cell cycle at the G0/G1 phase showed an obvious increase, and an opposite trend was observed in the S phase cells (Figures 6(h)–6(j)). The difference was statistically significant at a dose of 0.5 mg/mL in SKOV3 cells (P < 0.01) and 1 mg/mL in HEY cells (P < 0.01), implying that CFG induced the cell cycle of G0/G1 phase stagnation and shortened the S phase in OC cells. Furthermore, dose-dependent inhibition of MUC1, DICER1, and CDK2 expression by CFG was confirmed (Figures 6(k)–6(m)).

In vivo experiment showed that compared with the control group, the body weights of the nude mice in the CFG group slightly decreased (Figure 7(a)). Moreover, larger spot-like tumor nodules were observed in the lung of mice in the control group, compared with the CFG group (Figure 7(b)). IHC results revealed that the expressions of CDK2 and MUC1 expression levels were lowered in the CFG group compared to the control group (Figure 7(b)).

4. Discussion

4.1. Relationship between OC and CFG. Most women with OC show a poor prognosis because only 15% of OCs are discovered at the early stage. Although initial remission could be temporarily achieved by undergoing surgery and cytoreduction, followed by paclitaxel/carboplatin combination chemotherapy, OC can recur within a median of 16 months in patients with OC at the advanced stage [5]. Many clinical randomized-controlled trials have revealed that Chinese herbal medicine significantly enhances curative capacity and alleviates adverse effects, leading to improved...
Figure 6: Continued.
Migration rate

12 h 24 h

HEY

Control Low Middle High

SKOV3

Control Low Middle High

Figure 6: Continued.
**Figure 6:** Continued.
Figure 6: Continued.
chemotherapy compliance and consequently ameliorative clinical outcomes [20].

Several TCM prescriptions are being used in the clinical cancer treatment. Accumulating studies have found that several natural chemicals included in traditional medications can successfully prevent tumor development with few side effects. However, as TCM is often used in combination with multiple drugs, its composition is relatively complex, and clarification of its specific mechanism of action is challenging. The extracts of fuzi inhibit cancer cell proliferation and migration [21–23]. Guizhi fuling pill strengthens the anticancer efficacy and sensitizes cisplatin-resistant OC cells by inactivating the PI3K/AKT/mTOR pathway [24].

4.2. Chemical Diversity of CFG Uncovered by MolNetEnhancer. To understand the specific components of CFG, we analyzed the alcohol extract of CFG by LC-MS/MS, and nearly 87 compounds were found, such as organooxygen compounds, carboxylic acids and derivatives, and benzene and substituted derivatives. The chemical diversity of the metabolites in CFG confirmed the diversity of CFG compounds and corroborated their effects on multiple targets and pathways in different ways.

4.3. Outcomes of Network Pharmacology, Molecular Docking, and Experimental Validation. The network pharmacology technique was used to investigate putative active compounds and herb targets. In the herbs, A total of 56 ingredients from the four herbs were discovered, and 32 of them were screened for further research. These ingredients affected 65 targets in FZ, 72 in CS, 45 in FL, and 3 in MTH. The representative common genes of the four herbs were MSN, GSTK1, DICER1, MUC1, CDK2, EP300, and SMARCA4.

DICER1, MUC1, and CDK2 were major putative targets of CFG in OC. DICER1, a tumor suppressor, is essential for microRNA synthesis, and its dysregulation has been intensively discovered in various cancer types [25]. A recent study reported that Dicer was shown to be overexpressed in the stroma of ovarian tumors, where it caused fibroblast activation from normal fibroblasts to carcinoma-associated fibroblasts (CAF), which fueled tumor invasion and metastasis [26]. Consistently, we speculated that the inhibition of DICER1 expression by CFG might be related to suppressing stromal inflammation. MUC1, a membrane-bound mucin, affects cell-to-cell and cell-extracellular matrix interactions and is essential for cancer cell migration [27]. Therefore, we speculated that MUC1 might act as a membrane surface receptor of CFG, and CFG might inhibit OC cell proliferation and migration by downregulating MUC1 expression.

The transition of the G1 to S phase is regarded as a key step in the cell cycle process, which makes the G1/S transition effective in restraining cancer cell proliferation [28]. Cyclin E mainly coordinates with CDK2 to promote G1/S cell cycle progression in OC cells and decrease CDK2 expression, resulting in cell cycle arrest in the G1 phase [29]. Molecular docking findings showed that the five primary chemicals, namely, baicalin, ignavine, lactiflorin, neokadsuranic acid B, and deoxyaconitine, of CFG had a strong affinity for CDK2. [30, 31].

4.4. Gene Enrichment and Pathway Analysis. Gene enrichment and pathway analysis showed that the antitumor effects of CFG on OC rely on immune system regulation, PI3K/Akt/mTOR pathway, ErbB signaling pathway, and CDC42 signaling. An earlier study found that the presence of intratumoral T cells is related to the prognosis of advanced OC [32]. Besides, researchers have found that OC is strongly correlated with defects in DNA repair mechanisms and activation of the innate immune system kill tumor cells [33]. The PI3K/AKT/mTOR pathway, which
plays a vital role in the regulation of cell survival, migration, and proliferation, is highly mutated in patients with OC, resulting in an unsatisfactory prognosis [34, 35]. ErbB and PI3K-related pathways are important regulators in the carcinogenesis of mucinous ovarian carcinoma [36]. CDC42 activity inhibition can inhibit the invasion and metastasis of OC [37].

Figure 7: Animal experiment results. (a) Weight changes in mice of control and CFG groups; (b) comparison of HE staining and immunohistochemical detection of CDK2 and MUC1 expression of lung tissue sections between the negative control group and CFG group in the lung metastatic nodules.

4.5. Conclusion and Limitations. In this study, network pharmacology was used to determine the potential anticancer effects of CFG, which were visualized by molecular docking for verification. The predicted antitumor effect was then confirmed by experimental validations. However, the following limitations exist and require further exploration: (1) the ingredients screened in this study may totally be different with that in the blood of the clinical patients; (2) the targets were not absolutely precise, which are affected by different target prediction tools; and (3) further experimental validation is needed to explore the inhibitory effects of the active compounds and targets of CFG on OC progression.

Data Availability

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.

Ethical Approval

The Institutional Animal Care and Use Committee of Zhejiang Chinese Medical University approved all animal procedures prior to the initiation of this study (Approval No. 2022-KL-099-01).
Conflicts of Interest
The authors declare no conflicts of interest.

Authors’ Contributions
FT acquired funds for the research; FT and ZZ designed the work; ZL, QL, LW, WL, and JL performed the experiment; ZL and NY analyzed the network pharmacology data; ZL and QL wrote the manuscript; ZZ and FT revised the manuscript. All of the authors approved the submitted version of the paper. Zhaoyi Li and Qingling Liu contributed equally to this work and should be considered as co-first authors.

Acknowledgments
The authors are thankful to Zhejiang Chinese Medical University for the assistance in conducting this study. This research was supported by the National Natural Science Foundation of China (No. 82074391), Natural Science Foundation of Zhejiang Province (No. LY21H270004) and Zhejiang Provincial Programme of TCM (No. 2019ZQ013).

Supplementary Materials

Supplementary 1. Supplementary Table 1: a total of 304 CFG-OC-related targets were screened out from TTD (n = 33) and DisGeNET (n = 271), respectively.

Supplementary 2. Supplementary Table 2: in total, 185 common gene targets were selected for OC and CFG molecules to build the ingredient-target database.

Supplementary 3. Supplemental Table 3: gene enrichment analysis revealed 51 (P < 0.05) signaling pathways in Reactome analysis.

Supplementary 4. Supplemental Table 4: gene enrichment analysis revealed 44 (P < 0.05) signaling pathways in FunRich analysis.

References
[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] L. A. Torre, B. Trabert, C. E. DeSantis et al., “Ovarian cancer statistics, 2018,” CA: a Cancer Journal for Clinicians, vol. 68, no. 4, pp. 284–296, 2018.
[3] D. Li, Q. J. Wu, F. F. Bi et al., “Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer,” American Journal of Translational Research, vol. 8, pp. 1601–1608, 2016.
[4] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2020,” CA: a Cancer Journal for Clinicians, vol. 70, no. 1, pp. 7–30, 2020.
[5] S. Moufarrij, M. Dandapani, E. Arthofer et al., “Epigenetic therapy for ovarian cancer: promise and progress,” Clinical Epigenetics, vol. 11, no. 1, p. 7, 2019.
[6] Z. Liu, T. T. Zhang, J. J. Zhao et al., “The association between overweight, obesity and ovarian cancer: a meta-analysis,” Japanese Journal of Clinical Oncology, vol. 45, no. 12, pp. 1107–1115, 2015.
[7] X. Zhang, Y. Feng, X. Y. Wang et al., “The inhibition of UBC13 expression and blockage of the DNM1T1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer,” Cell Death & Disease, vol. 9, no. 2, p. 93, 2018.
[8] S. Ruan, Z. Zhang, X. Tian et al., “Compound fuling granule suppresses ovarian cancer development and progression by disrupting mitochondrial function, galactose and fatty acid metabolism,” Journal of Cancer, vol. 9, no. 18, pp. 3382–3393, 2018.
[9] A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008.
[10] Y. Zhang, Y. Li, X. Mao et al., “Thyroid hormone synthesis: a potential target of a Chinese herbal formula Haizao Yuhu Decoction acting on iodine-deficient goiter,” Oncotarget, vol. 7, no. 32, pp. 51699–51712, 2016.
[11] T. T. Luo, Y. Lu, S. K. Yan, X. Xiao, X. L. Rong, and J. Guo, “Network pharmacology in research of Chinese medicine formula: methodology, application and prospective,” Chinese Journal of Integrative Medicine, vol. 26, no. 1, pp. 72–80, 2020.
[12] S. Li and B. Zhang, “Traditional Chinese medicine network pharmacology: theory, methodology and application,” Chinese Journal of Natural Medicines, vol. 11, no. 2, pp. 110–120, 2013.
[13] B. Boezio, K. Audouze, P. Ducrot, and O. Taboureau, “Network-based approaches in pharmacology,” Molecular Informatics, vol. 36, no. 10, p. 36, 2017.
[14] R. R. da Silva, M. Wang, L. F. Nothias et al., “Propagating annotations of molecular networks using in silico fragmentation,” PLoS Computational Biology, vol. 14, no. 4, article e1006089, 2018.
[15] H. Mohimani, A. Gurevich, A. Mikheenko et al., “Dereplication of peptidic natural products through database search of mass spectra,” Nature Chemical Biology, vol. 13, no. 1, pp. 30–37, 2017.
[16] J. J. van der Hooft, J. Wandy, M. P. Barrett, K. E. Burgess, and S. Rogers, “Topic modeling for untargeted substructure exploration in metabolomics,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 48, pp. 13738–13743, 2016.
[17] M. Ernst, K. B. Kang, A. M. Caraballo-Rodriguez et al., “MolNetEnhancer: enhanced molecular networks by integrating metabolome mining and annotation tools,” Metabolites, vol. 9, no. 7, p. 144, 2019.
[18] Y. Djoumbou Feunang, R. Eisner, C. Knox et al., “ClassyFire: automated chemical classification with a comprehensive, computable taxonomy,” Journal of Cheminformatics, vol. 8, no. 1, p. 61, 2016.
[19] T. Freichel, V. Heine, D. Laaf et al., “Sequence-defined heteromultivalent precision glycomacromolecules bearing sulfonated/sulfated Nonglycosidic moieties preferentially bind galectin-3 and delay wound healing of a galectin-3 positive tumor cell line in an in vitro wound scratch assay,” Macromolecular Bioscience, vol. 20, no. 9, article e2000163, 2020.
[20] R. Wang, Q. Sun, F. Wang et al., “Efficacy and safety of Chinese herbal medicine on ovarian cancer after reduction surgery and adjuvant chemotherapy: a systematic review and meta-analysis,” Frontiers in Oncology, vol. 9, p. 730, 2019.
"Synergetic effects of aqueous extracts of Fuzi (Radix Aconiti Lateralis Preparata) and Tubeimu (Rhizoma Bolbostemmatis) on MDA-MB-231 and SKBR3 cells," *Journal of Traditional Chinese Medicine*, vol. 36, no. 1, pp. 113–124, 2016.

X. J. Huang, W. Ren, J. Li, L. Y. Chen, and Z. N. Mei, "Anti-inflammatory and anticancer activities of ethanol extract of pendulous monkshood root in vitro," *Asian Pacific Journal of Cancer Prevention*, vol. 14, no. 6, pp. 3569–3573, 2013.

Q. Zhang, X. Chen, Y. Luo, H. Ren, and T. Qiao, "Fuzi enhances anti-tumor efficacy of radiotherapy on lung cancer," *Journal of Cancer*, vol. 8, no. 19, pp. 3945–3951, 2017.

L. Han, X. Guo, H. Bian et al., "Guizhi Fuling Wan, a traditional Chinese herbal formula, sensitizes cisplatin-resistant human ovarian cancer cells through inactivation of the PI3K/AKT/mTOR pathway," *Evidence-based Complementary and Alternative Medicine*, vol. 2016, Article ID 4651949, 2016.

X. Wang, H. Chen, Y. Wen et al., "Dicer affects cisplatin-mediated apoptosis in epithelial ovarian cancer cells," *Molecular Medicine Reports*, vol. 18, no. 5, pp. 4381–4387, 2018.

Z. Yang, P. Jin, S. Xu et al., "Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer," *Cancer Letters*, vol. 415, pp. 20–29, 2018.

N. Jonckheere and I. Van Seuningen, "The membrane-bound mucins: from cell signalling to transcriptional regulation and expression in epithelial cancers," *Biochimie*, vol. 92, no. 1, pp. 1–11, 2010.

M. Liu, H. Liu, and J. Chen, "Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (review)," *Oncology Reports*, vol. 39, no. 3, pp. 901–911, 2018.

Y. Han, Y. Wei, J. Yao et al., "Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERα expression in high-grade serous ovarian carcinoma," *American Journal of Cancer Research*, vol. 10, no. 4, pp. 1194–1206, 2020.

C. Gao, Y. Zhou, H. Li et al., "Antitumor effects of baicalin on ovarian cancer cells through induction of cell apoptosis and inhibition of cell migration in vitro," *Molecular Medicine Reports*, vol. 16, no. 6, pp. 8729–8734, 2017.

Y. Li, D. Wang, J. Liu et al., "Baicalin attenuates YAP activity to suppress ovarian cancer stemness," *Oncotargets and Therapy*, vol. Volume 13, pp. 7151–7163, 2020.

L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., "Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer," *The New England Journal of Medicine*, vol. 348, no. 3, pp. 203–213, 2003.

A. Farolfi, G. Gurioli, P. Fugazzola et al., "Immune system and DNA repair defects in ovarian cancer: implications for locoregional approaches," *International Journal of Molecular Sciences*, vol. 20, no. 10, p. 2569, 2019.

M. K. Ediriweera, K. H. Tennekoon, and S. R. Samarakoon, "Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance," *Seminars in Cancer Biology*, vol. 59, pp. 147–160, 2019.

A. Ghoneum and N. Said, "PI3K-AKT-mTOR and NFκB pathways in ovarian cancer: implications for targeted therapeutics," *Cancers (Basel)*, vol. 11, no. 7, p. 949, 2019.